| 摘要 |
<p>The invention relates to synthetic peptide mixtures which elicit T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment. Preferred peptides are RAS p21 (5-21, 49-73 and 52-70) mutant peptides and in particular the mutants G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, Q61K, Q61L and Q61R.</p> |
